Murigenics
9.3/10 Overall Rating
No Reviews Yet
18 Orders Completed
vallejo, California, US
MuriGenics offers and delivers robust preclinical in-vivo and in-vitro contract drug discovery and development services, supported with statistical validation, solid science and project management to companies throughout the United States.
Our growth is driven by repeat customers who recognize that MuriGenics delivers on-time, quality results.
Our lead scientists bring over 50 years of experience and expertise to the table. In the past year, our scientific team has specialized in developing protocols, integrating in-vivo and in-vitro assays for our clients. Such innovation has minimized use of resources while maximizing information obtained from a single study.
We specialize in disease models for oncology, cardiovascular, inflammation and metabolic diseases. Please inquire about any additional models.
Determining the pharmacokinetics (PK) of novel test compounds is essential for approximating efficacy during the drug development and discovery phases. At MuriGenics, we provide a wide-range of murine pharmacokinetic, bioavailability and biodistribution services that can be customized to meet the needs of our clients.
In order to screen for possible gene-compound interactions, MuriGenics provides preclinical pharmacogenetic PK profiling through the use of a variety of strains of rats or mice. In addition, a PK component can be added to a Disease Model study to assess changes within PK parameters during a particular disease state.
As with all of our in vivo services, we guarantee continued communication during on-going studies and will contact you directly with any questions or concerns. This helps to guarantee that any data collected is both biologically and clinically reliable and relevant.
Species
PK Dose Administration
A compound of interest is delivered via one of several routes. Typically, there are 3-5 animals/dose/group. Some studies may require several concentrations of a particular compound of interest or the use of different formulations and vehicles. Routes of administration available for drug delivery include:
Sampling Time Points
At various time points set forth in the study protocol, blood samples (tissue samples) will be collected and processed. The number of and distance between time points will be dependent upon the compound, the route of administration, and its half-life.
Biliary Pharmacokinetics
Biliary pharmacokinetic studies may be conducted to determine biliary excretion and clearance of test articles.
PK Analysis in Disease Models
Since the pharmacokinetics of a compound may change during disease influencing efficacy, PK studies may be performed in conjunction with Disease Models. Contact us to inquire about adding a PK component to one of our available disease models or to discuss a study idea of your own.
Cell-based assay development can range from cytotoxic assays, such as apoptosis, to cell proliferation, calcium mobilization, and cell-based immunoassays. Mechanisms of action, including receptor binding, receptor activation, cell signaling, drug internalization and subcellular localization can be delineated in cell-based assays following treatment with your pharmaceuticals.
If the standard animal models or cell-based assays don’t meet your needs, Murigenics will help you develop new models and experimental protocols to suit.
Bioassay development encompasses testing of conditioned medium, cell lysates or whole cells in a variety of formats these include ELISA and Luminex immunoassays along with immunohistochemical methods such as flow cytometry.
Additionly, MuriGenics has GxP capabilities through the use of the FlexStation3 system, a multiplatform, high-throughput instrument. This platform has a wide range of applications for cell and bioassays.
MuriGenics performs a variety of in vitro toxicity screens and assays. Performing in vitro cytotoxicity assays prior to animal testing may be a cheaper alternative for initial drug screens. Since many of these tests require cell-based assays, our experience in cell biology, enables us to analyze cells using molecular and biochemical techniques as well as morphologically.
In Vitro Myelotoxicity
Myelotoxicity is a serious side-effect of many chemotherapeutic and immune-suppressive agents. This condition can lead to serious life-threatening infection and neutropenic sepsis. MuriGenics provides a panel of screens designed to help our clients gain insight into the likelihood and degree to which their compounds may produce myelotoxicity and thus aid them in lead candidate selection. Below is our panel of screens:
In Vitro Hepatotoxicity – Rat
Drug-induced hepatic injury is a common reason for the withdrawal of an approved drug. Drug-induced hepatotoxicity ranges from asymptomatic elevation of liver enzymes to fulminant hepatic failure. We perform a series of assay screens that may be utilized throughout the discovery and development phases in conjunction with traditional in vivo methods to aid the client in the selection of a lead compound. Below is a list of assessments that we perform:
Allotransplantation
Airpouch
Contact Hypersensitivity & Delayed-Type Hypersensitivity
Dermal
Hepatitis
Inflammatory Bowel Disease (IBD)
Local Inflammation
Peritonitis
Pulmonary Inflammation (Lung Injury)
Renal Acute Inflammation
Sepsis
Obesity, Diabetes and Metabolic Syndrome
Renal Failure
Steatosis
Non-Obese Diabetic (NOD Mice)
Drug Discovery & Development Services
Cytotoxicity Assays Services
Murigenics has not received any reviews.
Murigenics has not received any endorsements.